LAHORE: Haleon, a consumer healthcare company, announced on Tuesday that it is enhancing its production capacity of Panadol in Pakistan as part of a $12 million investment plan.
The initiative, launched in 2023 and set to be completed by the end of 2026, aims to strengthen the availability of the over-the-counter medicine.
Haleon CEO Qawi Naseer emphasised that the company’s focus is to empower people with accessible healthcare solutions.
During a ceremony, Mr Naseer further highlighted that Haleon’s demerger from GSK in 2022 has allowed for greater flexibility and autonomy to support local growth and innovation.
Published in Dawn, July 30th, 2025
